PAI
Palo Alto Investors Portfolio holdings
AUM $470M
1-Year Return
2.57%
This Quarter Return
-3.89%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.66B
AUM Growth
-$158M
(-8.7%)
Cap. Flow
-$19.7M
Cap. Flow
% of AUM
-1.19%
Top 10 Holdings %
Top 10 Hldgs %
76.19%
Holding
43
New
1
Increased
5
Reduced
3
Closed
1
Top Buys
| 1 |
AstraZeneca
AZN
|
+$12.1M |
| 2 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$10.5M |
| 3 |
Alkermes
ALKS
|
+$3.17M |
| 4 |
Amicus Therapeutics
FOLD
|
+$1.07M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
+$837K |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
+$17.4M |
| 2 |
STAAR Surgical
STAA
|
+$16.4M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
+$11.1M |
| 4 |
Prothena Corp
PRTA
|
+$3.29M |
Sector Composition
| 1 | Healthcare | 96.14% |
| 2 | Financials | 2.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABMD
1
DELISTED
Abiomed Inc
ABMD
| $179M | 10.8% |
549,820
-34,113
| -6% | -$11.1M |
|
2
BioMarin Pharmaceuticals
BMRN
$10.4B
| $171M | 10.32% |
2,212,950
| – | – |
|
3
Insmed
INSM
$30.6B
| $166M | 10.01% |
6,019,106
| – | – |
|
|
4
STAAR Surgical
STAA
$1.35B
| $147M | 8.85% |
1,140,511
-127,300
| -10% | -$16.4M |
|
5
United Therapeutics
UTHR
$18B
| $127M | 7.66% |
687,206
| – | – |
|
|
6
Prothena Corp
PRTA
$439M
| $120M | 7.25% |
1,685,282
-46,200
| -3% | -$3.29M |
|
7
Biogen
BIIB
$21.1B
| $102M | 6.18% |
361,600
| – | – |
|
|
8
Amicus Therapeutics
FOLD
$2.47B
| $96.6M | 5.83% |
10,114,043
+111,600
| +1% | +$1.07M |
|
|
RVNC
9
DELISTED
Revance Therapeutics, Inc.
RVNC
| $89.2M | 5.38% |
3,201,866
| – | – |
|
10
Vanda Pharmaceuticals
VNDA
$264M
| $65M | 3.92% |
3,791,805
| – | – |
|
11
eHealth
EHTH
$121M
| $46.4M | 2.8% |
1,145,870
| – | – |
|
12
Acadia Pharmaceuticals
ACAD
$4.04B
| $38.8M | 2.34% |
2,337,877
| – | – |
|
13
Align Technology
ALGN
$9.56B
| $36.9M | 2.23% |
55,405
| – | – |
|
|
EPZM
14
DELISTED
Epizyme, Inc
EPZM
| $35.1M | 2.12% |
6,856,513
| – | – |
|
15
Karyopharm Therapeutics
KPTI
$54.3M
| $31.3M | 1.89% |
358,870
| – | – |
|
|
SAGE
16
DELISTED
Sage Therapeutics
SAGE
| $27.4M | 1.65% |
617,930
+17,430
| +3% | +$772K |
|
|
GRTS
17
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $25.4M | 1.54% |
2,356,282
| – | – |
|
18
Gossamer Bio
GOSS
$728M
| $22.3M | 1.35% |
1,772,950
| – | – |
|
|
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
| $20M | 1.21% |
4,484,411
| – | – |
|
|
20
Alkermes
ALKS
$4.52B
| $18.2M | 1.1% |
589,900
+102,800
| +21% | +$3.17M |
|
|
DRNA
21
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $17.3M | 1.04% |
855,713
+523,000
| +157% | +$10.5M |
|
|
22
AstraZeneca
AZN
$240B
| $12.1M | 0.73% |
+201,489
| New | +$12.1M |
|
23
AnaptysBio
ANAB
$543M
| $11.8M | 0.71% |
436,592
| – | – |
|
24
Puma Biotechnology
PBYI
$228M
| $9.77M | 0.59% |
1,392,997
| – | – |
|
|
25
Syndax Pharmaceuticals
SNDX
$1.3B
| $8.5M | 0.51% |
444,900
+43,800
| +11% | +$837K |
|